-- Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanisms of Action --DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 31, 2025 (GLOBE…
V-DIFFERENCE is first study to show that Leqvio prioritized after statins helps more patients achieve guideline low-density lipoprotein cholesterol (LDL-C)…
Phase III trial informed by comprehensive KARDIA data set generated through three Phase II studies: KARDIA-1, KARDIA-2 and KARDIA-3In the…
MIAMI, FL / ACCESS Newswire / August 30, 2025 / In today's fast-paced world, maintaining mental sharpness, focus, and memory…
MIAMI BEACH, FLORIDA / ACCESS Newswire / August 30, 2025 / Nutriessential, a U.S.-based professional-grade dietary supplement provider, proudly announces…
-- 2025 ESC/EAS Dyslipidemia Guideline Focused Update Reaffirms High Dose Icosapent Ethyl as Class IIA Recommended Therapy in High-Risk or…
- Acoramidis demonstrated a significant reduction in risk of CVM through 42 months post-randomization, with a 44% hazard reduction, setting…
Positive Trial Demonstrates Superiority of Aficamten to Standard-of-Care Beta-Blocker Metoprolol Primary Endpoint Result Consistent Across All Prespecified Subgroups Company to…
VANCOUVER, BC / ACCESS Newswire / August 29, 2025 / GLG Life Tech Corporation (TSX:GLG) ("GLG" or the "Company"), a…
SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / August 29, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company…